The Pharma and Biotech M&A Trends 2009-2014 report
provides comprehensive understanding and unprecedented access to the merger and
acquisition agreements entered into by the worlds leading biopharma companies.
The report provides a detailed understand and analysis of how and why companies
enter merger and acquisition deals.
Understanding the flexibility of a prospective partner’s
negotiated deals terms provides critical insight into the negotiation process
in terms of what you can expect to achieve during the negotiation of terms.
Whilst many smaller companies will be seeking details of the payments clauses,
the devil is in the detail in terms of how payments are triggered – contract
documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of all
merger and acquisition deals announced since 2009 as recorded in the Current
Agreements deals and alliances database, including financial terms where
available, plus links to online copies of actual merger and acquisition contract
documents as submitted to the Securities Exchange Commission by companies and
their partners.
Contract documents provide the answers to numerous
questions about a prospective partner’s flexibility on a wide range of
important issues, many of which will have a significant impact on each party’s
ability to derive value from the deal.
The initial chapters of this report provide an
orientation of M&A dealmaking and business activities.
Chapter 1 provides
an introduction to the report, whilst
chapter 2 provides an analysis of the
trends in M&A as well as a discussion on the merits of the type of deal.
Chapter 3 provides an overview of the structure of
M&A deals. The chapter includes numerous case studies to enable
understanding of M&A deals.
Chapter 4 provides a review of the leading M&A deals
since 2009. Deals are listed by headline value, signed by bigpharma and and
most active of all biopharma companies. Where the deal has an agreement
contract published at the SEC a link provides online access to the contract via
the Current Agreements deals and alliances database.
Chapter 5 provides a comprehensive listing of the top 50
big pharma companies (with M&A announements) with a brief summary followed
by a comprehensive listing of M&A deals available in the public domain.
Where available, each deal title links via Current Agreements deals and
alliances database to an online version of the actual contract document,
providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive listing of the top 50
big biotech companies (with M&A announements) with a brief summary followed
by a comprehensive listing of M&A deals available in the public domain.
Where available, each deal title links via Current Agreements deals and
alliances database to an online version of the actual contract document,
providing easy access to each contract document on demand.
Chapter 7 provides a comprehensive and detailed review of
M&A deals signed and announced since 2009 where a contract document is
available. Contract documents provide an indepth insight into the actual deal
terms agreed between the parties with respect to the M&A deal.
In addition the report includes a comprehensive listing
of all M&A deals announced since 2009. Each listing is organized as an
appendix by company A-Z, and industry sector. Each deal title links via
hyperlink to an online version of the deal record including, where available,
the actual contract document.
The report also includes numerous table and figures that
illustrate the trends and activities in M&A
dealmaking since 2009.
In conclusion, this report provides everything a
prospective dealmaker needs to know about M&A alliances.
Pharma and Biotech
M&A Trends 2009-2014 report provides the reader with the following key
benefits:
- In-depth understanding of M&A deal trends since 2009
- Analysis of the structure of M&A agreements with numerous real life case studies
- Comprehensive access to over 2,500 actual M&A deals entered into by the world’s biopharma companies
- Detailed access to actual M&A deals entered into by the leading fifty bigpharma companies
- Insight into the terms included in a M&A agreement, together with real world clause examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Spanning
over 1677 pages, “Pharma and Biotech
M&A Trends 2009-2014” report covering the Trends in M&A dealmaking,
Overview of M&A deal structure, Leading M&A deals, Big pharma M&A
deals, Big biotech M&A deals, M&A contracts directory. The report
covered companies few are - Abbott Laboratories, Abbvie, Abraxis BioScience,
Abraxis Health, Accelerated Care Plus, AccelPath, Accelrys, Accuray, Acon Labs,
Acorda Therapeutics, Actavis, Actavis (acquired by Watson), Actinium
Pharmaceuticals
Know more about this
report at : http://mrr.cm/ZWL
No comments:
Post a Comment
Note: only a member of this blog may post a comment.